Evaluating the clinical relevance of a ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year guidage alzheimer's prevention trial
Auteur(s) :
Coley, Nicola [Auteur]
Gallini, Adeline [Auteur]
Ousset, Pierre-Jean [Auteur]
Vellas, Bruno [Auteur]
Andrieu, Sandrine [Auteur]
Gallini, Adeline [Auteur]
Ousset, Pierre-Jean [Auteur]
Vellas, Bruno [Auteur]
Andrieu, Sandrine [Auteur]
Titre de la revue :
Alzheimer's & dementia . the journal of the Alzheimer's Association
Nom court de la revue :
Alzheimers Dement
Numéro :
12
Pagination :
1216-1225
Date de publication :
2016-12-01
ISSN :
1552-5279
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Composite cognitive scores have been developed as primary outcome measures for preclinical/prevention trials for Alzheimer's disease (AD), mainly using observational data and with little consideration of clinical ...
Lire la suite >Composite cognitive scores have been developed as primary outcome measures for preclinical/prevention trials for Alzheimer's disease (AD), mainly using observational data and with little consideration of clinical relevance. Secondary analysis of placebo group data from a 5-year AD prevention trial. The composite score was the average of the following z scores: MMSE orientation items, Free and Cued Selective Reminding Test, Category Fluency, Trail Making Test-part B. Composite score change from baseline differed significantly by age, APOE genotype, and CDR progression and AD dementia status. A 1 point decrease in baseline score was highly predictive of 5-year AD dementia risk (HR = 3.51, 95% CI, 2.62-4.71, P < .001). The 1 year minimum clinically important difference was estimated at -0.3 points and predicted AD dementia. We explored the clinical relevance of a composite score in a prevention trial setting. This type of analysis facilitates the interpretation of composite scores and informs power calculations.Lire moins >
Lire la suite >Composite cognitive scores have been developed as primary outcome measures for preclinical/prevention trials for Alzheimer's disease (AD), mainly using observational data and with little consideration of clinical relevance. Secondary analysis of placebo group data from a 5-year AD prevention trial. The composite score was the average of the following z scores: MMSE orientation items, Free and Cued Selective Reminding Test, Category Fluency, Trail Making Test-part B. Composite score change from baseline differed significantly by age, APOE genotype, and CDR progression and AD dementia status. A 1 point decrease in baseline score was highly predictive of 5-year AD dementia risk (HR = 3.51, 95% CI, 2.62-4.71, P < .001). The 1 year minimum clinically important difference was estimated at -0.3 points and predicted AD dementia. We explored the clinical relevance of a composite score in a prevention trial setting. This type of analysis facilitates the interpretation of composite scores and informs power calculations.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T13:02:53Z